First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.

• Main Authors: Piha-Paul, Sarina A, Geva, Ravit, Tan, Tira J, Lim, Darren Wt, Hierro, Cinta, Doi, Toshikiko, Rahma, Osama, Lesokhin, Alexander, Luke, Jason John, Otero, Javier, Nardi, Lisa, Singh, Angad, Xyrafas, Alexandros, Chen, Xinhui, Mataraza, Jennifer, Bedard, Philippe L
• Other Authors: DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
• Format: Article
• Published: BMJ 2022
• Subjects: antibodies; clinical trials as topic; combination; drug therapy; investigational; neoplasm; therapies; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Glucocorticoid-Induced TNFR-Related Protein; Humans; Immune Checkpoint Inhibitors; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/218496
• Institution: National University of Singapore

10.1136/jitc-2021-002863